136 related articles for article (PubMed ID: 17285276)
1. Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Ammatuna E; Ottone T; Zaza S; Lavorgna S; Grillo R; Curzi P; Panetta P; Federici G; Amadori S; Lo-Coco F
Ann Hematol; 2007 May; 86(5):355-61. PubMed ID: 17285276
[TBL] [Abstract][Full Text] [Related]
2. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
3. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].
Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529
[TBL] [Abstract][Full Text] [Related]
4. JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic prospects.
Benmoussa A; Dehbi H; Fehri S; Quessar A; Nadifi S
Pathol Biol (Paris); 2011 Aug; 59(4):e89-92. PubMed ID: 19939582
[TBL] [Abstract][Full Text] [Related]
5. Concomitant BCR-ABL1 translocation and JAK2(V617F) mutation in three patients with myeloproliferative neoplasms.
Hummel JM; Kletecka MC; Sanks JK; Chiselite MD; Roulston D; Smith LB; Czuchlewski DR; Elenitoba-Johnson KS; Lim MS
Diagn Mol Pathol; 2012 Sep; 21(3):176-83. PubMed ID: 22847163
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Masykura N; Habibah U; Selasih SF; Gani S; Irawan C; Somoastro S; Handoyo Utomo AR
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):220-227. PubMed ID: 30772299
[TBL] [Abstract][Full Text] [Related]
7. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
8. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
[TBL] [Abstract][Full Text] [Related]
9. Molecular diagnosis of myeloproliferative neoplasms.
Patnaik MM; Tefferi A
Expert Rev Mol Diagn; 2009 Jul; 9(5):481-92. PubMed ID: 19580432
[TBL] [Abstract][Full Text] [Related]
10. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment.
Tefferi A; Barbui T
Mayo Clin Proc; 2005 Sep; 80(9):1220-32. PubMed ID: 16178503
[TBL] [Abstract][Full Text] [Related]
11. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
12. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.
Chen Q; Lu P; Jones AV; Cross NC; Silver RT; Wang YL
J Mol Diagn; 2007 Apr; 9(2):272-6. PubMed ID: 17384221
[TBL] [Abstract][Full Text] [Related]
13. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.
Aranaz P; Ormazábal C; Hurtado C; Erquiaga I; Calasanz MJ; García-Delgado M; Novo FJ; Vizmanos JL
Cancer Genet Cytogenet; 2010 May; 199(1):1-8. PubMed ID: 20417861
[TBL] [Abstract][Full Text] [Related]
14. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
[TBL] [Abstract][Full Text] [Related]
15. Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders.
Ghaderi M; Strömberg O; Porwit A
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):122-6. PubMed ID: 19016916
[TBL] [Abstract][Full Text] [Related]
16. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
[TBL] [Abstract][Full Text] [Related]
17. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
18. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
19. JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: experience of a major referral center in Lebanon.
Mahfouz RA; Hoteit R; Salem Z; Bazarbachi A; Mugharbel A; Farhat F; Ziyadeh A; Ibrahim A; Taher A
Genet Test Mol Biomarkers; 2011 Apr; 15(4):263-5. PubMed ID: 21198321
[TBL] [Abstract][Full Text] [Related]
20. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]